Hereditary Angioedema
What is Hereditary Angioedema?
Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling (angioedema) affecting the skin, mucous membranes, and internal organs. The condition primarily affects the face, lips, tongue, throat, hands, feet, and genitals, and can cause life-threatening swelling of the upper airway. HAE affects approximately 1 in 50,000 people worldwide, with symptoms typically beginning in childhood or adolescence. The disorder is caused by deficiencies or dysfunction of proteins that regulate inflammation and blood vessel permeability, leading to unpredictable swelling attacks that can last 2-5 days without treatment.
Key statistics
| Statistic | Value |
|---|---|
| Global prevalence | 1 in 50,000 people |
| Age of onset | Usually before age 20 (can occur at any age) |
| Mortality rate | 15-33% without treatment (due to airway obstruction) |
| Diagnostic delay | Average 8-10 years from symptom onset |
Symptoms
Primary symptoms: Recurrent swelling episodes, abdominal pain, nausea, vomiting, difficulty swallowing, voice changes, skin swelling.
The hallmark of HAE is asymmetric, non-pitting swelling that develops over several hours and resolves spontaneously over 2-5 days. Skin swelling most commonly affects the face (especially eyelids and lips), hands, feet, and genitals, creating a characteristic asymmetric appearance. Laryngeal angioedema causes voice changes, difficulty swallowing, and potentially fatal airway obstruction. Gastrointestinal attacks present with severe cramping abdominal pain, nausea, vomiting, and diarrhea, often mimicking acute surgical conditions. Some patients experience a non-raised, serpentine rash called erythema marginatum before attacks. Unlike allergic angioedema, HAE swelling is not accompanied by hives (urticaria) or itching, and episodes can occur without obvious triggers, though stress, trauma, infection, or hormonal changes may precipitate attacks.
Causes and risk factors
HAE is caused by mutations in genes affecting the complement system and kallikrein-kinin pathway. Type I HAE (85% of cases) results from mutations in the SERPING1 gene causing low levels of C1 esterase inhibitor protein. Type II HAE (15% of cases) involves the same gene but produces dysfunctional protein with normal levels. Type III HAE involves mutations in other genes including F12, PLG, ANGPT1, KNG1, MYOF, and HS3ST6, typically affecting women more severely.
The condition follows an autosomal dominant inheritance pattern, meaning each child of an affected parent has a 50% chance of inheriting the mutation. However, approximately 25% of cases result from spontaneous (de novo) mutations with no family history. Risk factors for attack frequency and severity include female hormones (estrogen increases attack frequency), physical trauma, emotional stress, infections, certain medications (ACE inhibitors, estrogen-containing contraceptives), and dental procedures.
Prevention
Currently, there is no known way to prevent Hereditary Angioedema, as it is an inherited genetic condition. However, early detection through genetic screening and carrier testing can help families make informed decisions about family planning and enable prompt treatment initiation. Genetic counseling is recommended for affected individuals and their families to understand inheritance risks and reproductive options. Preventive measures focus on avoiding known triggers, using short-term prophylaxis before medical procedures, and having emergency medications readily available. Long-term prophylactic treatment may be recommended for patients experiencing frequent or severe attacks.
Complications
The most serious complication of HAE is laryngeal angioedema, which can cause complete airway obstruction and death within hours if untreated. Studies show that up to 50% of HAE patients will experience at least one laryngeal attack during their lifetime. Gastrointestinal attacks can lead to severe dehydration, electrolyte imbalances, and unnecessary surgical interventions when misdiagnosed as acute abdomen. Chronic complications include anxiety and depression related to unpredictable attacks, reduced quality of life, and social isolation. Repeated swelling episodes may cause permanent tissue changes and scarring. Without proper treatment, patients may develop chronic pain syndromes and experience significant disruption to education, employment, and relationships.
Diagnosis
HAE diagnosis relies on clinical presentation, family history, and specific laboratory tests. Clinical criteria include recurrent angioedema without urticaria, family history of similar symptoms, and poor response to antihistamines or corticosteroids. Laboratory testing measures C4 complement levels (screening test), C1 esterase inhibitor antigen levels, and C1 esterase inhibitor functional activity. In Type I HAE, both antigen and functional levels are low, while Type II shows normal or elevated antigen with reduced function. Genetic testing can identify specific mutations and is particularly important for Type III HAE diagnosis when complement studies are normal. Additional tests may include tryptase levels to exclude mastocytosis and comprehensive family screening. The average diagnostic delay is 8-10 years, emphasizing the need for increased awareness among healthcare providers.
Treatment
HAE treatment involves three main approaches: acute attack management, short-term prophylaxis, and long-term prophylaxis. Acute treatment includes icatibant (bradykinin receptor antagonist), ecallantide (kallikrein inhibitor), and various C1 esterase inhibitor concentrates including berinert and ruconest. Fresh frozen plasma may be used when specific treatments are unavailable, though it carries risks.
Long-term prophylaxis is recommended for patients with frequent attacks and includes lanadelumab (subcutaneous kallikrein inhibitor), regular C1 esterase inhibitor infusions, and oral medications like danazol or stanozolol (attenuated androgens). Short-term prophylaxis before dental procedures or surgery typically involves C1 esterase inhibitor concentrate or high-dose danazol.
Emergency management of laryngeal attacks may require intubation or emergency tracheostomy. Patients should carry emergency medication and wear medical alert identification.
Prognosis
With proper treatment, HAE patients can achieve near-normal life expectancy and quality of life. Modern targeted therapies have dramatically reduced mortality rates from the historical 15-33% to less than 2% in well-managed patients. Early diagnosis and treatment access are crucial factors in prognosis. Patients with access to on-demand acute treatments experience shorter attack duration (hours instead of days) and reduced severity. Those on effective prophylactic therapy may experience 70-90% reduction in attack frequency.
Without treatment, HAE significantly impacts life expectancy due to fatal laryngeal attacks and reduces quality of life through unpredictable, painful swelling episodes. Long-term complications of untreated disease include chronic anxiety, depression, and social isolation. The prognosis varies by HAE type, with Type III sometimes showing milder symptoms but potentially greater hormone sensitivity.
Quality of life
Living with HAE requires comprehensive management strategies and lifestyle adaptations. Patients should maintain emergency action plans, carry rescue medications at all times, and wear medical alert identification. Regular follow-up with HAE specialists helps optimize treatment regimens and monitor for complications.
Lifestyle modifications include stress management techniques, gentle exercise programs (avoiding contact sports that may trigger attacks), and maintaining good oral hygiene to prevent infections. Dietary considerations focus on staying well-hydrated and avoiding known trigger foods if identified. Sleep hygiene is important as fatigue may increase attack susceptibility.
Mental health support is crucial, as HAE significantly impacts psychological well-being. Counseling, support groups, and patient education help manage anxiety about unpredictable attacks. Many patients benefit from cognitive behavioral therapy to develop coping strategies. Workplace and school accommodations may include flexible schedules for medical appointments and attack management. Patient advocacy organizations provide valuable resources for navigation of insurance coverage and treatment access.
Pregnancy and fertility
HAE significantly impacts pregnancy planning and management. The condition does not affect fertility, but hormonal changes during pregnancy can dramatically alter attack patterns. Many women experience increased attack frequency and severity, particularly during the first trimester, while others may see improvement.
Estrogen-containing contraceptives and hormone replacement therapy typically worsen HAE symptoms and should be avoided. Progesterone-only contraceptives are generally safe alternatives. During pregnancy, danazol and other androgens are contraindicated due to teratogenic effects. C1 esterase inhibitor concentrates are considered safe for treating acute attacks during pregnancy.
Genetic counseling is essential, as each child has a 50% chance of inheriting the condition. Prenatal genetic testing is available for families with known mutations. Delivery planning should include HAE emergency protocols and immediate access to treatment, as labor and delivery can trigger severe attacks. Breastfeeding is generally safe, though medication compatibility should be reviewed with specialists.
Children
Pediatric HAE presents unique challenges and considerations. Symptoms often begin in childhood, with the average age of first attack being 8-12 years, though onset can occur in infancy. Children may experience different attack patterns than adults, with gastrointestinal symptoms sometimes predominating over skin swelling.
Growth and development are typically normal unless frequent attacks cause nutritional deficiencies or chronic illness. School accommodations may include emergency action plans, medication storage protocols, and flexible attendance policies for attack management and medical appointments.
Treatment options in children are more limited, with fewer approved medications and dosing challenges. Icatibant and C1 esterase inhibitor concentrates are generally considered safe and effective in pediatric patients. Androgens like danazol require careful monitoring due to potential effects on growth and sexual development.
Family education and age-appropriate patient education help children understand their condition and develop self-management skills. Transition planning to adult care should begin in adolescence, ensuring continuity of specialized HAE management.
When to see a doctor
Seek emergency medical attention immediately for any swelling involving the face, tongue, throat, or difficulty breathing, swallowing, or speaking. Voice changes, stridor (high-pitched breathing sounds), or sensation of throat tightness require immediate emergency care, as these may indicate life-threatening airway swelling.
Seek urgent medical care for severe abdominal pain with nausea and vomiting, especially if accompanied by a history of similar episodes or family history of HAE. New-onset recurrent swelling episodes without obvious cause warrant prompt evaluation.
Schedule routine medical appointments for recurrent unexplained swelling, family history of similar symptoms, or if current HAE treatments are not controlling symptoms adequately. Regular follow-up every 3-6 months is recommended for diagnosed patients to monitor treatment effectiveness and adjust therapy as needed.
Patients with known HAE should establish care with specialists experienced in the condition and maintain emergency action plans with their healthcare providers.
Regional context
Limited data exists regarding HAE prevalence and characteristics specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. The condition likely affects these populations at similar rates to global averages, though genetic founder effects or specific mutations may exist in isolated populations. Healthcare infrastructure and medication availability for HAE management may vary significantly across the region, potentially impacting diagnosis and treatment access.
Regional challenges may include limited specialist availability, restricted access to newer HAE-specific medications, and potential delays in emergency treatment. GMJ welcomes contributions from regional researchers to build the evidence base for Hereditary Angioedema in the Caucasus, particularly regarding local prevalence, genetic variants, and healthcare delivery models.
Research and clinical trials
Current HAE research focuses on developing new therapeutic targets, improving prophylactic treatments, and advancing gene therapy approaches. Recent breakthroughs include the approval of lanadelumab for long-term prophylaxis and ongoing studies of oral kallikrein inhibitors.
Promising research directions include gene therapy trials using CRISPR technology to correct C1 esterase inhibitor deficiency, novel oral medications for acute treatment, and improved prophylactic agents with extended dosing intervals. Biomarker research aims to predict attack frequency and treatment response.
Clinical trials are actively recruiting patients for studies of new treatments, improved delivery methods, and combination therapies. Patients can find current trials through ClinicalTrials.gov using search terms “hereditary angioedema” or specific drug names. Participation in clinical trials may provide access to promising new treatments while contributing to advancement of HAE care.
Frequently asked questions
Is hereditary angioedema the same as allergic swelling?
No, HAE differs significantly from allergic angioedema. HAE swelling occurs without hives, doesn’t respond to antihistamines or epinephrine, and often has no identifiable trigger. Allergic angioedema typically occurs with urticaria, responds to standard allergy treatments, and has clear triggers.
Can HAE be cured?
Currently, there is no cure for HAE, but highly effective treatments can prevent attacks and treat acute episodes. With proper management, most patients can live normal, productive lives. Gene therapy research shows promise for potential future cures.
How is HAE inherited?
HAE follows autosomal dominant inheritance, meaning each child of an affected parent has a 50% chance of inheriting the condition. However, about 25% of cases result from new mutations with no family history.
What triggers HAE attacks?
Common triggers include physical trauma, emotional stress, infections, hormonal changes (menstruation, pregnancy), certain medications (ACE inhibitors), and dental procedures. However, many attacks occur without identifiable triggers.
Can people with HAE live normal lives?
Yes, with proper diagnosis and treatment, most HAE patients can maintain normal life expectancy and quality of life. Early diagnosis, access to emergency medications, and appropriate prophylactic therapy when needed are key to successful management.
Support and resources
- HAE International (HAEI) – Global patient organization: www.haei.org
- US Hereditary Angioedema Association – Patient advocacy and education: www.haea.org
- Orphanet – Rare disease information portal: www.orpha.net (ORPHA:91378)
- National Organization for Rare Disorders (NORD) – www.rarediseases.org
- EURORDIS – European rare disease organization: www.eurordis.org
- International Association of Hereditary Angioedema – Medical professional organization
- HAE Canada – Canadian patient organization: www.haecanada.org
Related conditions
- Acquired Angioedema – Non-hereditary form often associated with autoimmune conditions or medications
- Idiopathic Angioedema – Recurrent swelling without identifiable cause or complement abnormalities
- Mast Cell Activation
Cite this page
GMJ News Desk. “Hereditary Angioedema.” GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/condition/hereditary-angioedema/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?
In the news